¼¼°èÀÇ È¯ÀÚ ¸ÅĪÀ» À§ÇÑ ÀΰøÁö´É(AI) ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ½ÃÀå
Artificial Intelligence-based Clinical Trial Solutions for Patient Matching
»óǰÄÚµå : 1644162
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 142 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ȯÀÚ ¸ÅĪÀ» À§ÇÑ ÀΰøÁö´É(AI) ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ¼¼°è ½ÃÀå, 2030³â±îÁö 24¾ï ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇÒ Àü¸Á

2024³â 6¾ï 4,160¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ȯÀÚ ¸ÅĪÀ» À§ÇÑ ÀΰøÁö´É(AI) ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ¼¼°è ½ÃÀåÀº 2024-2030³â°£ 24.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 24¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¾¾çÇÐ ¿ëµµ´Â CAGR 25.3%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ µ¿¾È 6¾ï 4,890¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ë»ç¼º Áúȯ ¿ëµµ ºÎ¹®Àº ºÐ¼® ±â°£ µ¿¾È CAGR 24.5%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 6,870¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 23.5%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ È¯ÀÚ ¸ÅĪÀ» À§ÇÑ ÀΰøÁö´É(AI) ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ½ÃÀåÀº 2024³â 1¾ï 6,870¸¸ ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È 23.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2030³â±îÁö 3¾ï 6,920¸¸ ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ºÐ¼® ±â°£ µ¿¾È °¢°¢ 22.7%¿Í 21.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¾à 17.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ȯÀÚ ¸ÅĪÀ» À§ÇÑ ÀΰøÁö´É(AI) ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

AI´Â ÀÓ»ó½ÃÇè¿¡¼­ ȯÀÚ ¸ÅĪ¿¡ ¾î¶² Çõ¸íÀ» °¡Á®¿Ã °ÍÀΰ¡?

ÀΰøÁö´É(AI)Àº ÀÓ»ó½ÃÇè Âü¿©ÀÚ È®ÀÎÀÇ ¼Óµµ, Á¤È®¼º, È¿À²¼ºÀ» Å©°Ô Çâ»ó½ÃÅ´À¸·Î½á ÀÓ»ó½ÃÇèÀÇ È¯ÀÚ ¸ÅĪÀ» Çõ½ÅÀûÀ¸·Î º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ÀÓ»ó½ÃÇè ȯÀÚ ¸ðÁý ¹æ½ÄÀº ½Ã°£ÀÌ ¿À·¡ °É¸®°í ¿À·ù¿Í Áö¿¬ÀÌ ¹ß»ýÇϱ⠽¬¿î ¼öÀÛ¾÷¿¡ ÀÇÁ¸ÇÏ´Â °æ¿ì°¡ ¸¹¾Ò´Âµ¥, AI ±â¹Ý ¼Ö·ç¼ÇÀº °í±Þ ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀ» Ȱ¿ëÇÏ¿© ÀüÀڰǰ­±â·Ï(EHR), À¯ÀüÀÚ µ¥ÀÌÅͺ£À̽º, º´·Â µî ¹æ´ëÇÑ ¾çÀÇ È¯ÀÚ µ¥ÀÌÅ͸¦ ºÐ¼®ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾Ë°í¸®ÁòÀº ÀÓ»ó½ÃÇèÀÇ Æ¯Á¤ ±âÁØÀ» ÃæÁ·ÇÏ´Â Àû°Ý Âü°¡ÀÚ¸¦ ½Äº°ÇÏ¿© º¸´Ù Ÿ°ÙÆÃµÇ°í È¿°úÀûÀÎ ¸ðÁý ÇÁ·Î¼¼½º¸¦ º¸ÀåÇÕ´Ï´Ù.

ÀÇ»çÀÇ ¸Þ¸ð³ª ¿µ»óÁø´Ü °á°ú¿Í °°Àº ºñÁ¤Çü µ¥ÀÌÅ͸¦ ó¸®ÇÒ ¼ö ÀÖ´Â AIÀÇ ´É·ÂÀº ȯÀÚ ¸ÅĪ¿¡ ÀÖ¾î ¶Ç ´Ù¸¥ ȹ±âÀûÀÎ º¯È­ÀÔ´Ï´Ù. AI ½Ã½ºÅÛÀº °ü·Ã Á¤º¸¸¦ ÃßÃâÇϰí ÀÓ»ó½ÃÇè ¿ä°Ç°ú ´ëÁ¶ÇÏ¿© ´Ù¸¥ ¹æ¹ýÀ¸·Î´Â °£°úµÉ ¼ö ÀÖ´Â Èĺ¸ÀÚ¸¦ ¹ß°ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI´Â ÀÓ»ó½ÃÇè ÇÁ·ÎÅäÄÝÀÇ ¹ßÀü¿¡ µû¶ó ȯÀÚ ÀÚ°ÝÀ» µ¿ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®ÇÒ ¼ö ÀÖ¾î ÀϰüµÇ°í ÃÖÀûÈ­µÈ ¸ðÁý ÇÁ·Î¼¼½º¸¦ º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È¿À²¼ºÀº ÀÓ»ó½ÃÇèÀÇ Áö¿¬À» ÁÙÀÌ°í ¼º°ø °¡´É¼ºÀ» ³ô¿© ÀÓ»ó½ÃÇè »ýŰ迡¼­ AI´Â Çʼö ºÒ°¡°áÇÑ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè ȯÀÚ ¸ÅĪ¿¡ AI¸¦ µµÀÔÇÏ´Â ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

ÀÓ»ó½ÃÇèÀÇ º¹À⼺°ú °³ÀÎÈ­µÈ ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ȯÀÚ ¸ÅĪ¿¡ AI ±â¹Ý ¼Ö·ç¼ÇÀÌ µµÀԵǰí ÀÖ½À´Ï´Ù. Á¤¹Ð ÀÇÇÐÀÌ È®»êµÊ¿¡ µû¶ó ÀÓ»ó½ÃÇè¿¡´Â ¸Å¿ì ±¸Ã¼ÀûÀÎ À¯ÀüÀû, Àα¸ Åë°èÇÐÀû, ÀÓ»óÀû ÇÁ·ÎÆÄÀÏÀ» °¡Áø Âü°¡ÀÚ°¡ ÇÊ¿äÇϸç, AI´Â ´ë±Ô¸ð µ¥ÀÌÅÍ ¼¼Æ®¸¦ ¼±º°Çϰí ÀÌ·¯ÇÑ Á¤È®ÇÑ ±âÁØÀ» ÃæÁ·ÇÏ´Â °³ÀÎÀ» ½Äº°ÇÏ´Â µ¥ Ź¿ùÇÏ¿© Çö´ë ÀÓ»ó ¿¬±¸ÀÇ ÁÖ¿ä °úÁ¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. Çö´ë Àӻ󿬱¸ÀÇ Áß¿äÇÑ °úÁ¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ´É·ÂÀº Àû°Ý Âü°¡ÀÚ¸¦ ã±â°¡ ƯÈ÷ ¾î·Á¿î Èñ±ÍÁúȯ ÀÓ»ó½ÃÇè¿¡¼­ ƯÈ÷ °¡Ä¡°¡ ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ÀÓ»ó½ÃÇèÀÇ ºñ¿ë°ú ±â°£ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¦¾à»çµéÀº È¿À²¼ºÀ» ³ôÀ̱â À§ÇØ AI¸¦ Ȱ¿ëÇÑ ¼Ö·ç¼ÇÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ ¸ðÁýÀº ÀÓ»ó½ÃÇè °úÁ¤¿¡¼­ °¡Àå Å« º´¸ñ Çö»óÀ¸·Î, ÀÌ ´Ü°èÀÇ Áö¿¬Àº Å« ÀçÁ¤Àû ¼Õ½Ç·Î À̾îÁú ¼ö ÀÖÀ¸¸ç, AI´Â ÀÌ °úÁ¤À» °£¼ÒÈ­ÇÏ°í ¸ðÁý ±â°£À» ´ÜÃàÇÏ¿© ÀÓ»ó½ÃÇèÀ» ´õ ºü¸£°Ô ÁøÇàÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ AI Ȱ¿ë¿¡ ´ëÇÑ Áö¿øÀº µ¥ÀÌÅÍ »óÈ£¿î¿ë¼º Çâ»ó°ú ÇÔ²² ÀÌ·¯ÇÑ ±â¼úÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀ» Á¾ÇÕÇϸé, ÀÓ»ó½ÃÇè¿¡¼­ ȯÀÚ ¸ÅĪ ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ ÀÖ¾î AI°¡ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù.

AI°¡ ÀÓ»ó½ÃÇèÀÇ °øÁ¤¼º°ú Á¢±Ù¼ºÀ» °³¼±ÇÒ ¼ö ÀÖÀ»±î?

AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼ÇÀº ÀÓ»ó½ÃÇèÀÇ °øÁ¤¼º°ú Á¢±Ù¼ºÀ» °³¼±ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿ª»çÀûÀ¸·Î ÀÓ»ó½ÃÇè¿¡¼­ ƯÁ¤ Àα¸Åë°èÇÐÀû Áý´ÜÀÇ °ú¼Ò ´ëÇ¥¼ºÀº ½É°¢ÇÑ ¹®Á¦·Î, ÆíÇâµÈ °á°ú¸¦ ÃÊ·¡ÇÏ°í ¿¬±¸ °á°úÀÇ ÀϹÝÈ­ °¡´É¼ºÀ» Á¦ÇÑÇØ ¿ÔÀ¸¸ç, AI´Â ÀÓ»ó½ÃÇè ÀÚ°Ý ±âÁØÀ» ÃæÁ·ÇÏ´Â ´Ù¾çÇÑ È¯ÀÚ Áý´ÜÀ» ½Äº°ÇÏ°í º¸´Ù Æø³Ð°Ô ´ëÇ¥¼ºÀ» È®º¸ÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ö ÀÖ½À´Ï´Ù. AI ½Ã½ºÅÛÀº ÀÓ»ó Á¤º¸¿Í ÇÔ²² »çȸ Àα¸ Åë°èÇÐÀû µ¥ÀÌÅ͸¦ ºÐ¼®ÇÔÀ¸·Î½á ½ÇÁ¦ ȯÀÚ Áý´ÜÀÇ ´Ù¾ç¼ºÀ» ¹Ý¿µÇÏ´Â º¸´Ù Á¾ÇÕÀûÀÎ ¸ðÁý °úÁ¤À» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, AI ±â¹Ý Ç÷§ÆûÀº ¿ø°Ý ¹× ºÐ»êÇü ÀÓ»ó½ÃÇè ¸ðµ¨À» °¡´ÉÇÏ°Ô ÇÏ¿©, ÀÇ·á ¼­ºñ½º°¡ ºÎÁ·ÇÑ Áö¿ªÀ̳ª Áö¸®ÀûÀ¸·Î ¸Ö¸® ¶³¾îÁø Áö¿ªÀÇ Âü°¡Àڵ鿡°Ô ´õ ¸¹Àº Á¢±Ù¼ºÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ¿ø°Ý ÀÇ·á ¹× ¸ð¹ÙÀÏ Çコ ¼Ö·ç¼ÇÀ» Ȱ¿ëÇÏ¿© ȯÀÚ¸¦ Âü¿©½Ã۰í, ÀÓ»ó½ÃÇè ½Ã¼³·Î ÀÚÁÖ À̵¿ÇØ¾ß ÇÏ´Â ºÒÆíÇÔÀ» ÁÙ¿©ÁÝ´Ï´Ù. ÀÌ´Â °Åµ¿ÀÌ ºÒÆíÇϰųª Àü¹® ÀÇ·á ½Ã¼³¿¡ Á¢±ÙÇϱ⠾î·Á¿î »ç¶÷µé¿¡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °ÝÂ÷¸¦ ÇØ¼ÒÇÔÀ¸·Î½á AI´Â ÀÓ»ó½ÃÇè Âü¿©¸¦ ¹ÎÁÖÈ­Çϰí, Æ÷¿ë¼ºÀ» ÃËÁøÇϸç, ÀÇÇÐ ¿¬±¸ÀÇ ÇýÅÃÀÌ ´õ ³Î¸® ÆÛÁú ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

AI ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ¿äÀÎÀº ¹«¾ùÀϱî?

ȯÀÚ ¸ÅĪÀ» À§ÇÑ ÀΰøÁö´É(AI) ±â¹Ý ÀÓ»ó½ÃÇè ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Àӻ󿬱¸ÀÇ °úÁ¦¸¦ ±Øº¹Çϱâ À§ÇØ ÀΰøÁö´É¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖÀ½À» ¹Ý¿µÇÕ´Ï´Ù. ÀÓ»ó½ÃÇè ¼³°èÀÇ º¹À⼺°ú ¸¸¼ºÁúȯ ¹× Èñ±ÍÁúȯÀÇ È®»êÀº ȯÀÚ ¸ðÁýÀ» È¿À²È­ÇÏ´Â AI ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇèÀÇ È¿À²¼ºÀ» ³ôÀÌ°í ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â AIÀÇ ´É·ÂÀº Á¦¾àȸ»ç¿Í ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO)À¸·ÎºÎÅÍ ¸¹Àº ÅõÀÚ¸¦ À̲ø¾î³»°í ÀÖ½À´Ï´Ù.

µ¥ÀÌÅÍ ÅëÇÕ ±â¼úÀÇ ¹ßÀü°ú °íǰÁúÀÇ ´ë±Ô¸ð ÇコÄÉ¾î µ¥ÀÌÅÍ ¼¼Æ®ÀÇ °¡¿ë¼ºÀÌ Áõ°¡ÇÔ¿¡ µû¶ó AI ±â¹Ý µµ±¸ÀÇ Ã¤ÅÃÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ÇコÄÉ¾î ±â±â ¹× ȯÀÚ Æ÷ÅÐ »ç¿ë Áõ°¡¿Í °°Àº ¼ÒºñÀÚ Çൿ Æ®·»µå´Â ȯÀÚ ¸ÅĪ¿¡ Ȱ¿ëµÉ ¼ö ÀÖ´Â ±ÍÁßÇÑ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ »ý¼ºÇϰí ÀÖ½À´Ï´Ù. Àӻ󿬱¸ÀÇ Çõ½ÅÀ» ÃËÁøÇϱâ À§ÇÑ ±ÔÁ¦Àû ³ë·Âµµ AI ±â¹Ý ¼Ö·ç¼ÇÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεé°ú AI ¾Ë°í¸®Áò ¹× Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀÌ °áÇյǾî AI°¡ ÀÓ»ó½ÃÇèÀÇ ¹Ì·¡¸¦ À§ÇÑ Ãʼ®À¸·Î ÀÚ¸® ÀâÀ¸¸é¼­ ½ÃÀåÀÇ ±Þ¼ÓÇÑ È®ÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¿ëµµ(Á¾¾çÇÐ ¿ëµµ, ´ë»ç¼º Áúȯ ¿ëµµ, ½Å°æÁúȯ ¿ëµµ, °¨¿°¼º Áúȯ ¿ëµµ, ¼øÈ¯±â Áúȯ ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Á¦¾àȸ»ç ÃÖÁ¾ ¿ëµµ, Çмú±â°ü ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(36°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market to Reach US$2.4 Billion by 2030

The global market for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching estimated at US$641.6 Million in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 24.8% over the analysis period 2024-2030. Oncology Application, one of the segments analyzed in the report, is expected to record a 25.3% CAGR and reach US$648.9 Million by the end of the analysis period. Growth in the Metabolic Diseases Application segment is estimated at 24.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.7 Million While China is Forecast to Grow at 23.5% CAGR

The Artificial Intelligence-based Clinical Trial Solutions for Patient Matching market in the U.S. is estimated at US$168.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$369.2 Million by the year 2030 trailing a CAGR of 23.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 22.7% and 21.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.1% CAGR.

Global Artificial Intelligence-Based Clinical Trial Solutions for Patient Matching Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing Patient Matching in Clinical Trials?

Artificial Intelligence (AI) is transforming patient matching in clinical trials by significantly improving the speed, accuracy, and efficiency of participant identification. Traditional methods of recruiting patients for clinical trials are often time-consuming and rely on manual processes that are prone to errors and delays. AI-based solutions leverage advanced machine learning algorithms to analyze vast amounts of patient data from electronic health records (EHRs), genetic databases, and medical histories. These algorithms identify eligible participants who meet the specific criteria for trials, ensuring a more targeted and effective recruitment process.

AI’s ability to process unstructured data, such as physician notes and imaging results, is another game-changer in patient matching. By extracting relevant information and cross-referencing it with trial requirements, AI systems can uncover candidates who might otherwise be overlooked. Furthermore, AI enables dynamic updates to patient eligibility as trial protocols evolve, ensuring a consistent and optimized recruitment process. This efficiency reduces trial delays and enhances the likelihood of success, making AI indispensable in the clinical trial ecosystem.

What Drives the Adoption of AI in Clinical Trial Patient Matching?

The increasing complexity of clinical trials and the growing demand for personalized medicine are driving the adoption of AI-based solutions in patient matching. As precision medicine gains traction, trials require participants with highly specific genetic, demographic, and clinical profiles. AI excels at sifting through large datasets to identify individuals who meet these precise criteria, addressing a critical challenge in modern clinical research. This capability is especially valuable for rare disease trials, where finding eligible participants can be particularly difficult.

Additionally, the rising cost and duration of clinical trials are prompting pharmaceutical companies to adopt AI-driven solutions to improve efficiency. Patient recruitment is a major bottleneck in the trial process, and delays in this phase can lead to significant financial losses. AI streamlines this process, reducing recruitment timelines and enabling trials to proceed faster. Regulatory support for the use of AI in healthcare, combined with advancements in data interoperability, is further boosting the adoption of these technologies. These factors collectively highlight the growing importance of AI in addressing the challenges of patient matching in clinical trials.

Can AI Improve Equity and Accessibility in Clinical Trials?

AI-based clinical trial solutions are playing a pivotal role in enhancing equity and accessibility in clinical research. Historically, underrepresentation of certain demographic groups in clinical trials has been a significant issue, leading to biased outcomes and limiting the generalizability of findings. AI can address this challenge by identifying diverse patient populations that align with trial eligibility criteria, ensuring broader representation. By analyzing socio-demographic data alongside clinical information, AI systems can facilitate more inclusive recruitment processes that reflect the diversity of real-world patient populations.

Moreover, AI-based platforms enable remote and decentralized trial models, expanding access to participants in underserved and geographically remote areas. These platforms leverage telehealth and mobile health solutions to engage patients, reducing the need for frequent travel to trial sites. This is particularly beneficial for individuals with limited mobility or access to specialized healthcare facilities. By bridging these gaps, AI is democratizing participation in clinical trials, fostering inclusivity and ensuring that the benefits of medical research are more widely distributed.

What’s Driving the Growth of the AI-Based Clinical Trial Solutions Market?

The growth in the Artificial Intelligence-Based Clinical Trial Solutions for Patient Matching market is driven by several critical factors, reflecting the increasing reliance on AI to overcome the challenges of clinical research. The escalating complexity of trial designs, coupled with the growing prevalence of chronic and rare diseases, is fueling demand for AI solutions that streamline patient recruitment. AI’s ability to enhance trial efficiency and reduce costs is also attracting significant investments from pharmaceutical companies and contract research organizations (CROs).

Advancements in data integration technologies and the increasing availability of large, high-quality healthcare datasets are further enabling the adoption of AI-driven tools. Consumer behavior trends, such as the increasing use of wearable health devices and patient portals, are generating valuable real-time data that can be leveraged for patient matching. Regulatory initiatives aimed at fostering innovation in clinical research are also supporting the growth of AI-based solutions. These factors, combined with continuous advancements in AI algorithms and cloud computing, are driving the market’s rapid expansion and positioning AI as a cornerstone in the future of clinical trials.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence-based Clinical Trial Solutions for Patient Matching market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application, Other Applications); End-Use (Pharmaceutical Companies End-Use, Academia End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â